These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 20673559

  • 1. Relapse prevention in first-episode schizophrenia--maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia.
    Gaebel W, Riesbeck M, Wölwer W, Klimke A, Eickhoff M, von Wilmsdorff M, Lemke M, Heuser I, Maier W, Huff W, Schmitt A, Sauer H, Riedel M, Klingberg S, Köpcke W, Ohmann C, Möller HJ, German Study Group on First-Episode Schizophrenia.
    J Clin Psychiatry; 2011 Feb; 72(2):205-18. PubMed ID: 20673559
    [Abstract] [Full Text] [Related]

  • 2. Pharmacological long-term treatment strategies in first episode schizophrenia--study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia.
    Gaebel W, Möller HJ, Buchkremer G, Ohmann C, Riesbeck M, Wölwer W, Von Wilmsdorff M, Bottlender R, Klingberg S.
    Eur Arch Psychiatry Clin Neurosci; 2004 Apr; 254(2):129-40. PubMed ID: 15146342
    [Abstract] [Full Text] [Related]

  • 3. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J.
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [Abstract] [Full Text] [Related]

  • 4. Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia.
    Gaebel W, Riesbeck M, Wölwer W, Klimke A, Eickhoff M, von Wilmsdorff M, Jockers-Scherübl MC, Kühn KU, Lemke M, Bechdolf A, Bender S, Degner D, Schlösser R, Schmidt LG, Schmitt A, Jäger M, Buchkremer G, Falkai P, Klingberg S, Köpcke W, Maier W, Häfner H, Ohmann C, Salize HJ, Schneider F, Möller HJ, German Study Group on First-Episode Schizophrenia.
    J Clin Psychiatry; 2007 Nov; 68(11):1763-74. PubMed ID: 18052570
    [Abstract] [Full Text] [Related]

  • 5. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.
    Weiden PJ, Schooler NR, Weedon JC, Elmouchtari A, Sunakawa A, Goldfinger SM.
    J Clin Psychiatry; 2009 Oct; 70(10):1397-406. PubMed ID: 19906343
    [Abstract] [Full Text] [Related]

  • 6. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies.
    Kane JM.
    J Clin Psychiatry; 2003 Oct; 64 Suppl 16():34-40. PubMed ID: 14680417
    [Abstract] [Full Text] [Related]

  • 7. The staging model in schizophrenia, and its clinical implications.
    Agius M, Goh C, Ulhaq S, McGorry P.
    Psychiatr Danub; 2010 Jun; 22(2):211-20. PubMed ID: 20562749
    [Abstract] [Full Text] [Related]

  • 8. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia.
    Csernansky JG, Mahmoud R, Brenner R, Risperidone-USA-79 Study Group.
    N Engl J Med; 2002 Jan 03; 346(1):16-22. PubMed ID: 11777998
    [Abstract] [Full Text] [Related]

  • 9. [Detection of early warning signs in schizophrenic patients. Possible applications in prevention of recurrence].
    Wiedemann G, Hahlweg K, Hank G, Feinstein E, Müller U, Dose M.
    Nervenarzt; 1994 Jul 03; 65(7):438-43. PubMed ID: 7800087
    [Abstract] [Full Text] [Related]

  • 10. Predictors of response and remission in the acute treatment of first-episode schizophrenia patients--is it all about early response?
    Schennach-Wolff R, Jäger M, Mayr A, Meyer S, Kühn KU, Klingberg S, Heuser I, Klosterkötter J, Gastpar M, Schmitt A, Schlösser R, Schneider F, Gaebel W, Seemüller F, Möller HJ, Riedel M.
    Eur Neuropsychopharmacol; 2011 May 03; 21(5):370-8. PubMed ID: 21255982
    [Abstract] [Full Text] [Related]

  • 11. A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia.
    Kane JM, Potkin SG, Daniel DG, Buckley PF.
    J Clin Psychiatry; 2011 Feb 03; 72(2):194-204. PubMed ID: 20673553
    [Abstract] [Full Text] [Related]

  • 12. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
    Lindenmayer JP, Eerdekens E, Berry SA, Eerdekens M.
    J Clin Psychiatry; 2004 Aug 03; 65(8):1084-9. PubMed ID: 15323593
    [Abstract] [Full Text] [Related]

  • 13. Treatment compliance of outpatients with schizophrenia: patient's attitudes, demographic, clinical and therapeutic variables.
    Stanković Z, Britvić D, Vuković O, Ille T.
    Psychiatr Danub; 2008 Mar 03; 20(1):42-52. PubMed ID: 18376330
    [Abstract] [Full Text] [Related]

  • 14. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
    Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W.
    J Clin Psychopharmacol; 1993 Feb 03; 13(1):25-40. PubMed ID: 7683702
    [Abstract] [Full Text] [Related]

  • 15. Risperidone long-acting therapy in stable patients with recently diagnosed schizophrenia.
    Macfadden W, Bossie CA, Turkoz I, Haskins JT.
    Int Clin Psychopharmacol; 2010 Mar 03; 25(2):75-82. PubMed ID: 20101185
    [Abstract] [Full Text] [Related]

  • 16. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia.
    Kane JM, Lauriello J, Laska E, Di Marino M, Wolfgang CD.
    J Clin Psychopharmacol; 2008 Apr 03; 28(2 Suppl 1):S29-35. PubMed ID: 18334910
    [Abstract] [Full Text] [Related]

  • 17. Duration of neuroleptic treatment and relapse rate: a 5-year follow-up study with haloperidol decanoate.
    Youssef HA.
    Clin Neuropharmacol; 1991 Apr 03; 14 Suppl 2():S16-21; discussion S22-3. PubMed ID: 1684308
    [Abstract] [Full Text] [Related]

  • 18. [Risperidone in the treatment of chronic schizophrenia: multicenter study comparative to haloperidol].
    López Ibor JJ, Ayuso JL, Gutiérrez M, Guimon J, Herraiz ML, Chinchilla A, Ayuso JL, González Pinto A, Eguiluz I, Fernández A.
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1996 Apr 03; 24(4):165-72. PubMed ID: 8984849
    [Abstract] [Full Text] [Related]

  • 19. The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable.
    Gharabawi G, Bossie C, Turkoz I, Kujawa M, Mahmoud R, Simpson G.
    J Nerv Ment Dis; 2007 Dec 03; 195(12):976-82. PubMed ID: 18091190
    [Abstract] [Full Text] [Related]

  • 20. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection.
    Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J.
    Int Clin Psychopharmacol; 2008 Nov 03; 23(6):325-31. PubMed ID: 18854720
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.